| Perseus Proteomics Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120136140 | ANTI-CADHERIN ANTIBODY - It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 μg/mL is 30% or more. | 05-31-2012 |
| 20120128694 | THERAPEUTIC AGENTS FOR ALZHEIMER'S DISEASE AND CANCER - To provide a therapeutic drug for Alzheimer's disease and/or a cancer. | 05-24-2012 |
| 20120039879 | STREPTAVIDIN HAVING LOW IMMUNOGENICITY AND USE THEREOF - It is an object of the present invention to provide a mutant streptavidin wherein the immunogenicity (antigenicity) in mammals of a streptavidin is reduced. The present invention provides a mutant streptavidin, which comprises an amino acid sequence in which (a) the arginine residue at position 72 is substituted with another amino acid residue, and (b) any one or more of the tyrosine residue at position 10, the tyrosine residue at position 71, the glutamic acid residue at position 89, the arginine residue at position 91, and the glutamic acid residue at position 104 are substituted with other amino acid residues, with respect to the amino acid sequence of a core streptavidin as shown in SEQ ID NO: 2, and which has decreased immunogenicity as compared with that of a wild-type streptavidin. | 02-16-2012 |
| 20120034706 | METHOD FOR ASSESSING INFLAMMATORY CONDITION - Provided a method for correctly assessing an inflammatory condition of a patient who is receiving a therapy with an IL-6 inhibitor. The method for assessing an inflammatory condition of a patient who is receiving an IL-6 inhibitor, including determining a PTX3 level of a sample derived from a patient who is receiving an IL-6 inhibitor. | 02-09-2012 |
| 20110288278 | DIAGNOSTIC AGENT AND THERAPEUTIC AGENT FOR PANCREATIC CANCER - The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody. | 11-24-2011 |
| 20110165179 | THERAPEUTIC AGENTS FOR ALZHEIMER'S DISEASE AND CANCER - To provide a therapeutic drug for Alzheimer's disease and/or a cancer. | 07-07-2011 |
| 20110082284 | Gene overexpressed in cancer - Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer. | 04-07-2011 |
| 20100316568 | DIAGNOSTIC AGENT AND THERAPEUTIC AGENT FOR PANCREATIC CANCER - The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody. | 12-16-2010 |
| 20100062449 | Method Of Measuring PTX3 With High Sensitivity - To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody. | 03-11-2010 |
| 20100041167 | DRUG FOR DIAGNOSING LARGE INTESTINAL CANCER AND/OR POLYP, OBSERVING POSTOPERATIVE COURSE AND MONITORING RECURRENCE - The present invention is directed to a method for diagnosing large intestinal cancer and/or polyp and a method for observing postoperative course or monitoring recurrence thereof, wherein each method includes detecting cystatin SN protein by use of an anti-cystatin SN antibody. The present invention is able to provide a kit for assaying cystatin SN, which can be used, in a simple manner, in a diagnosis performed prior to conventional barium enema examination and endoscopic examination which impose burdens on patients; as an indicator of metastasis and recurrence; and in the evaluation of therapeutic effects. The present invention provides a method for diagnosing or monitoring large intestinal cancer and/or polyp which can be performed in a simple manner, and thus can allow to design a new regimen rapidly. | 02-18-2010 |
| 20090220524 | THERAPEUTIC AGENTS FOR ALZHEIMER'S DISEASE AND CANCER - To provide a therapeutic drug for Alzheimer's disease and/or a cancer. | 09-03-2009 |
| 20090192108 | Gene overexpressed in cancer - Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer. | 07-30-2009 |
| 20090092544 | Tumor diagnostic agent used in PET comprising anti-ROBO1 antibody - It is an object of the present invention to provide a novel antibody capable of specifically recognizing ROBO1 that is expressed in a cell membrane, a hybridoma that produces the above antibody, a method for producing the above antibody, and a tumor diagnostic agent used in PET comprising the above antibody. The present invention provides a monoclonal antibody capable of specifically recognizing ROBO1 existing on the surface of a cell, which is obtained by immunizing an animal to be immunized with a ROBO1-displaying budded baculovirus recovered from the culture supernatant of host cells infected with a recombinant baculovirus comprising the full-length cDNA of ROBO1 as an antigen. | 04-09-2009 |
